The efficacy of nivolumab in metastatic renal cell carcinoma (mRCC) has been proven. However, the nivolumab experience in Korean patients with mRCC is still poorly reported. We report initial experiences with the efficacy and safety of nivolumab in patients with mRCC. Materials and Methods: We retrospectively reviewed records for 25 patients with mRCC who had failed targeted therapy and were treated by nivolumab (2 mg/kg, every 2 weeks) at a single institution. The primary endpoint was objective response rate (ORR), and secondary endpoints were progression-free survival (PFS), safety profiles, and ORR in a programmed cell death receptor ligand 1 (PD-L1) expression subgroup. Results: The median age was 60 years and 16 patients (64%) were male. Objective responses were achieved in 8 patients (32.0%) (complete response, 1; partial response, 7). Median PFS was 3.0 months (95% confidence interval, 1.46-4.53). Treatment-related adverse events (AEs) of any grade were observed in 19 patients (76.0%) with 6 (24.0%) experiencing grade 3 to 4 treatment-related AEs. In subgroups by PD-L1 expression levels classified as 1% or greater and less than 1%, ORR was 50% and 0%, respectively. Conclusions: This study showed the efficacy and safety of initial experiences with nivolumab in Korean patients with mRCC who had failed targeted therapy. Our results were comparable to recent clinical trials on nivolumab in mRCC. (Korean J Urol Oncol 2019;17:96-102) Key Words: MetastasisㆍMonoclonal antibodyㆍProgrammed cell death 1 ligand 1ㆍRenal cell carcinomaㆍ Treatment outcome
INTRODUCTION
Every year, 338,000 renal cell carcinoma (RCC) patients are diagnosed worldwide 1 and about 30% of patients have metastatic disease at the time of diagnosis. 2 Many target therapies have been approved to treat advanced or metastatic RCC (mRCC) including vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target rapamycin (mTOR) inhibitors. VEGF pathway and mTOR inhibitors have been the main treatment agents for mRCC in the last decade. However, limitations of these drugs are in adverse events (AEs) and durable response. 3 Immuno-oncology drugs such as anti-programmed death 1 (PD1) and anti-CTLA4 have received attention for mRCC due to their long durable response and relatively fewer AEs.
Nivolumab is a fully human IgG4 antibody. It is a PD-1 immune checkpoint inhibitor that selectively blocks the interaction between PD-1, which is expressed on activated T cells, and programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2), which are expressed on immune cells and tumor cells. [4] [5] [6] This is the first approved agent for use in treatment-refractory clear cell RCC. 7 Motzer et al. 7 reported that nivolumab is effective and safe as a second-line treatment for advanced RCC. In a phase III trial, overall survival (OS) was longer and fewer grade 3 or 4 AEs occurred for nivolumab versus everolimus.
In Japanese patients, the efficacy and safety of nivolumab for mRCC was different from a previous global study. 8 Therefore, the efficacy and safety of immune checkpoint inhibitors for mRCC is expected to also be different in Korean populations compared to global populations. However, the experience for nivolumab in Korean patients with mRCC is still poorly reported. We report initial experiences on the efficacy and safety of nivolumab in Korean patients with mRCC previously treated with targeted therapy.
MATERIALS AND METHODS

Patients and Study Design
We retrospectively reviewed clinical data for 25 patients with 
Immunochemistry of tumor cells was performed using Dako
PD-L1 immunostaining kits (Agilent, Santa Clara, CA, USA).
Expression levels were classified according to presence or absence of quantifiable PD-L1 and were classified as more than 1% and less than 1%, as determined by a pathologist.
Patients were allowed to continue nivolumab after initial disease progression if clinical benefit was assessed and nivolumab had an acceptable side-effect profile. Safety assessments were conducted at each clinic visit. After treatment discontinuation, patient's last outpatient visit was confirmed for assessment of survival. AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Statistical Analysis
PFS and OS were estimated using Kaplan-Meier methodology. Statistical analysis was conducted using IBM SPSS Statistics ver. 23.0 (IBM Co., Armonk, NY, USA) with a p-value ＜0.05 considered statistically significant.
RESULTS
Patient Characteristics
Baseline characteristics of the 25 patients are in Table 1 Values are presented as number (%) unless otherwise indicated. IQR: interquartile range, ECOG: Eastern Cooperative Oncology Group, PD-L1: programmed death-ligand 1. 
Efficacy
Objective responses were observed in 32% of patients (8 of 25) ( . 1 ). Median PFS was 3 months (95% confidence interval, 1.38-4.61). Median OS was not reached (Fig. 2) . Quantifiable PD-L1 expression was observed in 5 patients (25%). PD-L1: programmed death-ligand 1. 
PD-L1 Expression
Among 25 patients, 20 tissues were available to be analyzed.
Quantifiable PD-L1 expression was observed in 5 patients (25%): 1 of 5 (20%) had less than 1% PD-L1 expression and 4 (80%) had more than 1% PD-L1 expression. Quantifiable PD-L1 expression levels in 5 patients and corresponding ORR are in Table 3 . Patients with less than 1% PD-L1 expression showed no objective response. Two patients with PD-L1 expression ≥1% showed objective response. Representative im- ages of positive and negative PD-L1 expression are in Fig. 3 .
Safety
Treatment-related AEs for all patients are in Table 4 .
Treatment-related AEs of any grade occurred in 19 of 25 patients (76%). The most common treatment-related AEs were nausea (9 patients, 36%), decreased appetite (7 patients, 28%), fatigue (7 patients, 28%), and pruritis (5 patients, 20%). Grade 
DISCUSSION
To our knowledge, this study is the first reported the effectiveness and safety of nivolumab for Korean patients with mRCC who had failed targeted therapy. We also found that the effect of an anti-PD1 inhibitor was dependent on PD-L1 expression level.
RCC is histologically known as an immune-related disease. 10 Interferon- (INF- ) and interleukin-2 (IL-2) have mainly been used to treat mRCC. 11 However, about 5% of patients showed a durable response to high-dose IL-2 but with significant
AEs. 12, 13 The treatment of mRCC has seen major changes since 2005. Several tyrosine kinase inhibitors (TKIs) targeting the VEGF pathway and mTOR inhibitors have been approved for managing mRCC. Pazopanib, sunitinib, temsirolimus, and bev-acizumab (in combination with INF- ) are approved as first-line treatment and everolimus, sorafenib, axitinib, and cabozantinib as second-line treatment. [14] [15] [16] [17] [18] Despite significant progress in treatment outcomes with these agents, the median OS for patients with mRCC is only 22-29 months. 18, 19 Remaining target therapies do not show significant OS benefits other than temsirolimus treatment. 20 resistance mechanism can improve the host immune response to tumors. 21, 22 In a large-scale, long-term, phase III trial, the immune checkpoint inhibitor nivolumab showed superior OS and higher ORR than everolimus for mRCC patients who had previous treatment such as TKIs. 7 In that trial, ORR was about 25% in the nivolumab group. 7 Our study had an ORR that was comparable to the previous study.
PFS in our study was shorter than in previous studies. 7, 8 Unlike previous studies that evaluated the efficacy of nivolumab as a second-line treatment after failure of first-line treatment, a majority of patients in our study received more than third-line nivolumab treatment. This difference may be the cause of differing results from previous studies.
In earlier studies, any grade AEs occurred in 79% of patients and grades 3-4 AEs in 19%. 7 A similar incidence rate of AEs was obtained in a Japanese subgroup 8 and in our study. This similarity suggests that the incidence of AEs of nivolumab is consistent regardless of race.
When efficacy according to PD-L1 expression was confirmed by immunohistochemical staining, OS was 21.8 in group with more than 1% expression and 27.4 months in a group with less than 1% expression in a previous study. 7 This result, although not evaluated for statistical significance, was contrary to expectations. In addition, no comparative analysis of ORR according PD-L1 expression level was performed. In contrast, in our study, ORR was higher in patients in the group with more than 1% expression. Although there was no statistical significance, this result suggested that the expression levels of PD-L1 and nivolumab efficacy may be related. However, the number of patients who underwent immunohistochemical staining was small, so validation of PD-L1 expression is required in a larger number of patients.
Our study had several limitations. It was retrospective and therefore had unavoidable bias such as bias in selection. A lack of clinical data and possible misclassification of registered patients may have influenced our results. Our study included a small number of patients and we used only a single tertiary center database. The median follow-up of our study was short, at 5 months. Because of this length, OS was not reached. The heterogeneity of previous systemic therapies may have produced more inferior results than expected.
CONCLUSIONS
In conclusion, we reported the initial experiences with anti-PD1 (nivolumab) treatment in Korean patients with mRCC who had failed targeted therapy. Our efficacy and safety data were comparable to data from recent clinical trials on nivolumab in mRCC. Our data provide valuable information on immuno-oncology drugs for treating mRCC that will be useful for real-world clinical practice.
